Accumulation of amyloid beta in the brain is a pathological hallmark of Alzheimer's disease, and the reduction of amyloid beta has been proposed as a primary therapeutic target. Mice immunized against amyloid beta and mice infused with anti-amyloid beta antibody (active and passive immunization, respectively) have reduced brain amyloid beta levels, and two mechanisms have been proposed: microgl...

protein amyloid beta (a?), as the pathologic hallmark of alzheimer disease (ad), increases in the brain of diabetic patients. the aim of this study was to investigate the effect of 6 weeks of voluntary wheel running combined with allium paradoxum extract on cortex amyloid beta (a?1-42) levels in diabetic rats induced with alloxan. for this purpose, 42 male wistar rats (weight 185+1 gr, 8 weeks ...

The popular amyloid hypothesis states that beta-amyloid protein aggregates to form sticky deposits in the brain tissue, causing Alzheimer’s disease. Current research studies propose that oligomeric morphologies of beta-amyloid are the principal pathogenic form of the protein. Through the use of a highly-specified capture enzyme-linked immunosorbent assay, the relative quantity of beta-amyloid o...

One of the notable features of Alzheimer's disease (AD) is the overabundance of beta-amyloid peptides in brain fluids, leading to the formation and deposition of insoluble amyloid plaques. Previous work in this lab demonstrates that the normal choroid plexus, a primary component of the blood-cerebrospinal fluid barrier, has the capacity to remove beta-amyloid from the cerebrospinal fluid, poten...

Cerebral deposition of beta-amyloid protein is a pathological feature central to Alzheimer's disease. Production of beta-amyloid by proteolytic processing of the beta-amyloid precursor protein (beta APP) is a critical initial step in beta-amyloidogenesis. We use an inhibitor of beta APP processing to block beta-amyloid peptide formation. Application of the inhibitor to cultured cells results in...

beta-Amyloid peptide accumulation plays a central role in the pathogenesis of Alzheimer's disease. Aberrant beta-amyloid buildup in the brain has been shown to be present both in the extracellular space and within neurons. Synapses are important targets of beta-amyloid, and alterations in synapses better correlate with cognitive impairment than amyloid plaques or neurofibrillary tangles. The li...

beta-Amyloid peptide is the major protein component of Alzheimer's plaques. When aggregated into amyloid fibrils, the peptide is toxic to neuronal cells. Here, an approach to the design of inhibitors of beta-amyloid toxicity is described; in this strategy, a recognition element, which interacts specifically with beta-amyloid, is combined with a disrupting element, which alters beta-amyloid aggr...

Amyloid beta-protein, the principal constituent of amyloid fibrils found in senile plaques and blood vessels in Alzheimer's disease, is constitutively produced and released into medium of cultured cells. Amyloid beta-protein is derived by proteolysis of the beta-amyloid precursor protein by unclear mechanisms. Beta-amyloid precursor protein is a transmembrane protein which can be processed to r...

introduction: although aging is the most important risk factor for alzheimer's disease (ad), there is evidence indicating that neuroinflammation may contribute to the development and progression of the disease. several studies indicated that minocycline may exert neuroprotective effects in rodent models of neurodegenerative diseases. nevertheless, there are also other studies implying that...